Sage Journals: Discover world-class research

Abstract

Liver disease is a clinical priority area identified by the RCGP, due to increasing levels of morbidity and mortality. Liver disease causes an estimated 8500 premature deaths in the UK annually, predominantly from a rise in non-alcoholic fatty liver disease, alcohol-related liver disease, and viral hepatitis. There has been a corresponding increase in liver function tests (LFTs) ordered from primary care, often as part of medication reviews or monitoring of chronic disease. GPs will therefore encounter an increasing number of abnormal LFTs in patients asymptomatic of liver disease. This article outlines a framework for investigating abnormal LFTs in primary care.

Get full access to this article

View all access options for this article.

References

Armstrong

Houlihan

Bentham

, et al. (2012) Presence and severity of non-alcoholic fatty liver disease in a large prospective primary care cohort. Journal of Hepatology 56(1): 234–240. DOI: 10.1016/j.jhep.2011.03.020.

BMUS Professional Standard Group (2015) BMUS recommended good practice guidelines: Justification of ultrasound requests. Available at: www.duc-ultrasound.co.uk/cms/resources/justification-for-us-bmus.pdf (accessed 21 March 2019).

Botros

Sikaris

(2013) The de Ritis ratio: the test of time. The Clinical Biochemist: Reviews 34(3): 117–130. Available at: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3866949 (accessed 11 April 2019).

Chopra S (2018) Clinical manifestations and natural history of chronic hepatitis C virus infection. Available at: www.uptodate.com/contents/overview-of-the-management-of-chronic-hepatitis-c-virus-infection (accessed 3 February 2019).

DeWeerdt

(2017) Disease progression: Divergent paths. Nature 551(7681): S92–S93. DOI: 10.1038/d41586-017-06925-2.

Donnan

McLernon

Dillon

, et al. (2009) Development of a decision support tool for primary care management of patients with abnormal liver function tests without clinically apparent liver disease: A record-linkage population cohort study and decision analysis (ALFIE). Health Technology Assessment (Winchester, England) 13(25): iii–iv, ix–xi, 1–134 DOI: 10.3310/hta13250.

Feld

Jacobson

Hézode

, et al. (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. The New England Journal of Medicine 373(27): 2599–2607. DOI: 10.1056/NEJMoa1512610.

Fracanzani

Valenti

Bugianesi

, et al. (2008) Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: A role for insulin resistance and diabetes. Hepatology (Baltimore, MD) 48(3): 792–798. DOI: 10.1002/hep.22429.

Friedman LS (2018) Approach to the patient with abnormal liver biochemical and function tests. Available at: www.uptodate.com/contents/approach-to-the-patient-with-abnormal-liver-biochemical-and-function-tests (accessed 30 January 2019).

10.

Hamilton P and Bickle I (2012) Liver function tests. In Data Interpretation for Medical Students, 2nd Edition. Knutsford: PasTest, pp.70–73.

11.

Jarvis

Hanratty

(2017) Detecting liver disease in primary care: Are we ready for change? The British Journal of General Practice 67(658): 202–203. DOI: 10.3399/bjgp17X690557.

12.

Johnston

(1999) Special considerations in interpreting liver function tests. American Family Physician 59(8): 2223–2230. Available at: www.aafp.org/afp/1999/0415/p2223.html (accessed 11 April 2019).

13.

Kasarala

Tillmann

(2016) Standard liver tests. Clinical Liver Disease 8(1): 13–18. DOI: 10.1002/cld.562.

14.

Lee RH and Tran TT (2017) Approach to liver disease occurring during pregnancy. Available at: www.uptodate.com/contents/approach-to-liver-disease-occurring-during-pregnancy (accessed 31 January 2019).

15.

Lee

Park

(2014) Radiologic evaluation of nonalcoholic fatty liver disease. World Journal of Gastroenterology 20(23): 7392–7402. DOI: 10.3748/wjg.v20.i23.7392.

16.

Lilford

Bentham

Girling

, et al. (2013) Birmingham and Lambeth Liver Evaluation Testing Strategies (BALLETS): A prospective cohort study. Health Technology Assessment 17(28): i–xiv, 1–307. DOI: 10.3310/hta17280.

17.

Lindor KD (2019) Intrahepatic cholestasis of pregnancy. Available at: www.uptodate.com/contents/intrahepatic-cholestasis-of-pregnancy (accessed 3 February 2019).

18.

National Institutes of Health (2017a) Clinical course and diagnosis of drug induced liver disease. Available at: https://livertox.nih.gov/ClinicalCourse.html#onset (accessed 11 April 2019).

19.

National Institutes of Health (2017b) Enzyme elevations without jaundice. Available at: https://livertox.nih.gov/Phenotypes_enzy.html (accessed 11 April 2019).

20.

Newsome

Cramb

Davison

, et al. (2018) Guidelines on the management of abnormal liver blood tests. Gut 67(1): 6–19. DOI: 10.1136/gutjnl-2017-314924.

21.

NICE (2016) Non-alcoholic fatty liver disease (NAFLD). Available at: www.nhs.uk/conditions/non-alcoholic-fatty-liver-disease/ (accessed 31 January 2019).

22.

RCGP. Clinical module 3.13: Digestive health. Available at: www.rcgp.org.uk/training-exams/training/gp-curriculum-overview/online-curriculum/applying-clinical-knowledge-section-1/3-13-digestive-health.aspx (accessed 7 February 2019).

23.

Sibai BM (2019) HELLP syndrome. Available at: www.uptodate.com/contents/hellp-syndrome (accessed 3 February 2019).

24.

Singh

Allen

Zhen

, et al. (2015) Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: A systematic review and meta-analysis of paired-biopsy studies. Clinical Gastroenterology and Hepatology: The Official Clinical Practice Journal of the American Gastroenterological Association 13(4): 643–654.e1–9. quiz e39–40. DOI: 10.1016/j.cgh.2014.04.014.

25.

Tang

C-M

Yau

(2014) Management of chronic hepatitis B infection: Current treatment guidelines, challenges, and new developments. World Journal of Gastroenterology 20(20): 6262–6278. DOI: 10.3748/wjg.v20.i20.6262.

Abnormal liver function tests

Abstract

Get full access to this article

References